Summary
GeneCode is developing a novel anti-PD drug that contains a central nervous system penetrant compound imitating GDNF peptide pathway activation that alleviates both motor and non-motor symptoms in PD patients, protecting and restoring lesioned dopamine neurons as well as potentially increasing dopamine levels in brain tissue. GeneCode’s unique solution uses small-molecule compounds that penetrate the blood-brain barrier, target the GFL receptor complex (containing GDNF protein) and mimic GFL (GNDF family of ligands) biological effects in neurons, promoting survival in the affected dopaminergic neuronal pathways. Once fully developed, the PD drug would be administered weekly or less frequently as an oral treatment. Considering the importance of GDNF family ligands and/or RET-signalling pathways for other groups of cells, applications of compounds developed by GeneCode are not limited to PD, but can be applied to cure other medical conditions such as neuropathic pain, addiction, ALS etc.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: | https://cordis.europa.eu/project/id/190151095 |
Start date: | 01-01-2024 |
End date: | 31-12-2025 |
Total budget - Public funding: | 2 338 056,00 Euro - 1 636 639,00 Euro |
Cordis data
Original description
GeneCode is developing a novel anti-PD drug that contains a central nervous system penetrant compound imitating GDNF peptide pathway activation that alleviates both motor and non-motor symptoms in PD patients, protecting and restoring lesioned dopamine neurons as well as potentially increasing dopamine levels in brain tissue. GeneCode’s unique solution uses small-molecule compounds that penetrate the blood-brain barrier, target the GFL receptor complex (containing GDNF protein) and mimic GFL (GNDF family of ligands) biological effects in neurons, promoting survival in the affected dopaminergic neuronal pathways. Once fully developed, the PD drug would be administered weekly or less frequently as an oral treatment. Considering the importance of GDNF family ligands and/or RET-signalling pathways for other groups of cells, applications of compounds developed by GeneCode are not limited to PD, but can be applied to cure other medical conditions such as neuropathic pain, addiction, ALS etc.Status
SIGNEDCall topic
HORIZON-EIC-2023-ACCELERATOROPEN-01Update Date
12-03-2024
Images
No images available.
Geographical location(s)